The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart ...

The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a ...

(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking ...

The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, discussing three abstracts, “Belzutifan + lenvatinib versus cabozantinib for ...

Safety and efficacy evaluation of nadofaragene firadenovec instilled into the renal pelvis in subjects with low-grade upper tract urothelial carcinoma (LG-UTUC): A single-arm, open-label phase 1/2 ...

Based on the NCCN 1.2026 guidelines for the management of CSI seminoma, surveillance is strongly preferred for pT1-pT3 tumors, and the NCCN does not recommend risk-adapted treatment for CSI seminoma ...

An optimal PSA response, defined as ≤0.2 ng/mL, is achieved by approximately 51% of mHSPC patients 6–8 months after treatment with androgen deprivation therapy (ADT) and androgen receptor pathway ...

These data represent the first published dosimetry data for our investigational formulation of Lu-177 zadavotide guraxetan, with projected mean cumulative renal doses remaining low for a six-cycle ...

Patients with advanced clear cell RCC whose disease progressed after 1-3 prior systemic therapies (including an anti–PD- [L]1 therapy) were randomly assigned 1:1 to belzutifan 200 mg or 120 mg daily: ...

ASCO GU 2026, Advanced Urothelial Bladder Cancer, FGFR3 genomic alterations in liquid biopsies, FoundationOne CDx assay, FGFR3 mutation.

(UroToday.com) The current standard of care for patients with localized muscle-invasive bladder cancer involves neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. Unfortunately, ...

ASCO 2025 Phase 1/2 Duravelo-1 study, nectin-4–targeting zelenectide pevedotin (BT8009), pembrolizumab, cisplatin-ineligible patients, locally advanced or metastatic urothelial cancer.